Starten Sie Ihre Suche...


Wir weisen darauf hin, dass wir technisch notwendige Cookies verwenden. Weitere Informationen

Augenklinik und Poliklinik

Klinikum / Johannes Gutenberg-Universität Mainz

Forschungsprojekte
Ergebnisse pro Seite:  10

2013 - 2015

Bimatoprost
  • Dr. Dr. Katrin

2013 - 2016

REPARO NGF 0212: An 8-week phase I/II, multicenter, randomized, double-masked, vehicle controlled parallel group study with a 48 or 56 week open-label follow-up period to evaluate the safety and efficacy of two doses (10µg/ml and 20µg/ml) of recombinant human nerve growth factor eye drops solution versus vehicle in patients with Stage 2 and 3 of neurotrophic keratitis.
  • Dr. Dr. Katrin

2013

EYEMUST: Glaucoma treatment by cyclo-coagulation using High Intensity Focused Ultrasound with the EyeOP1 medical device
  • Dr. Dr. Katrin

2013 - 2014

Validierungsstudie: Glaucogene Project
  • Dr. Dr. Katrin

2013 - 2020

Hydrus IV: THE SAFETY AND EFFECTIVENESS OF THE HYDRUS AQUEOUS IMPLANT FOR LOWERING INTRAOCULAR PRESSURE IN GLAUCOMA PATIENTS UNDERGOING CATARACT SURGERY, A PROSPECTIVE,MULTICENTER, RANDOMIZED, CONTROLLED CLINICAL TRIAL
  • Prof. Dr. Norbert

2013

LUMIGAN 056: A Multicentre, Double-Masked, Randomised, Active-controlled, Parallel Study of the Safety and Efficacy of Once-daily Bimatoprost Preservative-free Ophthalmic Solution Compared to Twice-daily Timolol Ophthalmic Solution in Paediatric Patients With Glaucoma
  • Dr. Dr. Katrin

2013

SANSIKA Extensionsstudie: Multizentrische, offene, interventionelle, prospektive, nicht-randomisierte Verlängerungsstudie für eine Kohorte, um die Nachhaltigkeit der Wirkung von NOVA22007 beim schwerwiegenden Syndrom des trockenen Auges nach Abbruch der Behandlung bei Patienten mit Besserung zu beurteilen.
  • Dr. Dr. Katrin

2013 - 2015

VEKTIS NOVA22007: Multicenter, randomized, double-masked, 3 parallel arms, vehicle-controlled, 4-month phase III trial with a 8 month safety follow-up period to evaluate the effficacy and safety of 2 dosing regimen of NOVA22007 1mg/ml eye drops, emulsion administered 4 times a day in pediatric patients with active severe vernal keratoconjunctivitis
  • Dr. Dr. Katrin

2013 - 2018

PRIDE (CRFB002DDE21): Multicenter randomized open-label three-arms controlled 12 months clinical proof of concept study to evaluate efficacy and safety of Ranibizumab alone or in combination with laser photocoagulation vs. laser photocoagulation alone in Proliferative Diabetic Retinopathy
  • Dr. Dr. Katrin

2013

Observation of treatment patterns with LuCEntis and real life ophthalmic monitoring, includ-ing optional OCT in Approved iNdications
  • Dr. Christina